Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30110431 | 0.91 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL29206786 | 0.90 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL7637773 | 0.90 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL5368414 | 0.89 | PDE4A (0.56) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL29944256 | 0.89 | PDE4A (0.56) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL27494780 | 0.89 | PDE4A (0.56) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL17144675 | 0.87 | PDE4A (0.67) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL28350552 | 0.87 | PDE4A (0.67) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL29356160 | 0.87 | PDE4A (0.67) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL8343201 | 0.87 | PDE4A (0.67) | PDE4ALMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112180007-B | Metabonomics-based diagnosis marker for generalized pustular psoriasis and application thereof | 上海市皮肤病医院 | 2023-08-18 | — | — | CN | disclosed |
| US-10646594-B2 | Deuterated metabolic water precursor for detecting and treating diseased tissue | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-05-12 | — | — | US | disclosed |
| US-10466253-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180259531-A1 | MEASUREMENT OF MOLECULAR FLUX RATES BY QUANTIFYING ISOTOPOLOGUE ABUNDANCES USING HIGH RESOLUTION MASS SPECTROMETRY | KINEMED, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-20170350903-A1 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-07 | — | — | US | disclosed |
| US-9778268-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-03 | — | — | US | disclosed |
| US-9720002-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-01 | — | — | US | disclosed |
| US-9043159-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-26 | — | — | US | disclosed |
| US-9037417-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling In Vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140295485-A1 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-02 | — | — | US | disclosed |
| US-8401800-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120115127-A1 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100322865-A1 | DEUTERATED METABOLIC WATER PRECURSOR FOR DETECTING AND TREATING DISEASED TISSUE | CASE WESTERN RESERVE UNIVERSITY | 2010-12-23 | — | — | US | disclosed |
| US-20100041082-A1 | METHODS FOR DETERMINING THE METABOLISM OF SUGARS AND FATS IN AN INDIVIDUAL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-18 | — | — | US | disclosed |
| US-7504233-B2 | Methods for determining the metabolism of sugars and fats in an individual | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-03-17 | — | — | US | disclosed |
| US-20060280682-A1 | Monitoring two dimensions of diabetes pathogenesis seperately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-14 | — | — | US | disclosed |
| US-20060020440-A1 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
| US-20050238577-A1 | Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050202406-A1 | Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-15 | — | — | US | disclosed |
| US-20040115131-A1 | Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115127-A1 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | GOT2, PC, PCK2 | PDE4A 2996/4885LMNA 3510/4885L3MBTL1 3694/4885 |
| US-20050238577-A1 | Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling | KLK3, MKI67, KRT18 | PDE4A 3796/4885LMNA 1374/4885L3MBTL1 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.